The company blamed a regulatory setback affecting development of its lead U.S. drug candidate linzagolix for uterine fibroids (UF), for which a new drug application (NDA) has been filed with the FDA. Linzagolix is a novel, once-daily, oral gonadotropin releasing hormone (GnRH) receptor antagonist designed to treat heavy menstrual bleeding associated with UF as well as pain associated with endometriosis . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post StockWatch: ObsEva Shares Crumble on Layoff Plans after FDA ‘Review Issues’ appeared first on GEN – Genetic Engineering and Biotechnology News.
